Association of circulating MtDNA with CVD in hemodialysis patients and in vitro effect of exogenous MtDNA on cardiac microvascular inflammation

Table 1 MHD subjects exhibit higher levels of plasma MtDNA

Variable	Healthy	Hemodialysis	t/χ²	p
Subject number	36	42
Age (years)	60.77 ± 8.98	59.40 ± 9.29	0.661	0.511
Male, n (%)	18 (50.0%)	25 (59.5%)	0.711	0.399
Dialysis vintage (years)	NS	3.76 ± 1.64
Hypertension, n (%)	8 (22.2%)	13 (30.9%)	0.751	0.386
Diabetes, n (%)	6 (16.7%)	16 (38.1%)	4.396	0.036
Hyperlipemia, n (%)	17 (47.2%)	15 (35.7%)	1.061	0.303
CHD, n (%)	2 (5.6%)	7 (16.7%)	2.345	0.126
Smoking, n (%)	6 (16.7%)	9 (21.4%)	0.283	0.595
Alcohol, n (%)	12 (33.3%)	10 (23.8%)	0.869	0.351
TC (mmol/L)	4.14 ± 0.93	4.49 ± 1.22	− 1.378	0.172
HDL-C (mmol/L)	1.24 ± 0.36	1.14 ± 0.28	1.338	0.185
LDL-C (mmol/L)	2.48 ± 1.09	2.38 ± 1.01	0.423	0.674
GH (%)	5.94 ± 1.13	6.69 ± 1.28	− 2.703	0.008
BUN (mmol/L)	5.89 ± 1.72	23.99 ± 5.75	− 18.163	0.000
SCr (umol/L)	68.01 ± 20.67	951.54 ± 177.05	− 29.741	0.000
Plasma MtDNA (10⁵ copies/mL)	2.41 ± 1.49	4.74 ± 1.85	− 6.043	0.000

CHD: Coronary heart disease; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; GH: glycosylated hemoglobin; BUN: blood urea nitrogen; SCr: serum creatinine; MtDNA: mitochondrial DNA

ISSN: 1471-2261